Express News | Korro Bio Has Submitted Regulatory Filing To Start Phase 1/2 Study Of KRRO-110 For Alpha-1 Antitrypsin Deficiency, First Participant Dosing Is Anticipated In Q1 Of 2025, With Interim Readout Is Expected In 2H Of 2025, And Completion Of Phase 1/2 Study...

BenzingaNov 4 07:32 ET

Express News | Korro Bio - Interim Readout Expected in H2 2025 & Completion of Phase 1/2 Study Anticipated in 2026

ReutersNov 4 07:25 ET

Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board

GlobeNewswireNov 4 07:25 ET

Express News | Korro Announces Regulatory Filing for Initiation of Krro-110 First-in-Human Study and Formation of Clinical Advisory Board

ReutersNov 4 07:25 ET

Piper Sandler Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $180

Moomoo NewsOct 24 07:36 ET · Ratings

Analysts Conflicted on These Healthcare Names: TransMedics Group (TMDX), Collegium Pharmaceutical (COLL) and Korro Bio (KRRO)

TipRanksOct 24 06:41 ET · Ratings